These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 20547892)

  • 1. ACP Journal Club. Nateglinide did not reduce diabetes or CV events in patients with impaired glucose tolerance and CV risk factors.
    Farkouh M
    Ann Intern Med; 2010 Jun; 152(12):JC6-10. PubMed ID: 20547892
    [No Abstract]   [Full Text] [Related]  

  • 2. ACP Journal Club. Valsartan reduced diabetes but not CV events in patients with impaired glucose tolerance and CV risk factors.
    Ann Intern Med; 2010 Jun; 152(12):JC6-9. PubMed ID: 20547903
    [No Abstract]   [Full Text] [Related]  

  • 3. ACP journal club. Intensive glucose control increased mortality and did not prevent CV events compared with standard glucose control in type 2 diabetes.
    Grubina R; Smith SA
    Ann Intern Med; 2011 May; 154(10):JC5-02. PubMed ID: 21576520
    [No Abstract]   [Full Text] [Related]  

  • 4. ACP Journal Club. Adding prompt revascularization to medical therapy did not reduce mortality or CV events in patients with type 2 diabetes and CAD.
    Poirier P
    Ann Intern Med; 2009 Oct; 151(8):JC4-5. PubMed ID: 19841443
    [No Abstract]   [Full Text] [Related]  

  • 5. ACP Journal Club. Daily n-3 fatty acid supplements did not reduce CV events in high-risk patients with dysglycemia.
    Lader E
    Ann Intern Med; 2012 Sep; 157(6):JC3-11. PubMed ID: 22986403
    [No Abstract]   [Full Text] [Related]  

  • 6. ACP Journal Club. Review: Intensive glucose control reduced some CV events but did not change mortality in type 2 diabetes.
    Lipscombe LL
    Ann Intern Med; 2009 Sep; 151(6):JC3-6. PubMed ID: 19755352
    [No Abstract]   [Full Text] [Related]  

  • 7. ACP Journal Club. Intensive and standard glucose control did not differ for major CV events or death in poorly controlled type 2 diabetes.
    Booth GL
    Ann Intern Med; 2009 Mar; 150(6):JC3-8. PubMed ID: 19306490
    [No Abstract]   [Full Text] [Related]  

  • 8. ACP Journal Club. Daily multivitamin supplements did not reduce risk for major CV events over > 10 years in men.
    Fairfield KM
    Ann Intern Med; 2013 Feb; 158(4):JC8. PubMed ID: 23420255
    [No Abstract]   [Full Text] [Related]  

  • 9. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
    Campbell IW
    Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ACP Journal Club. Review: Statins reduce mortality and cardiovascular (CV) morbidity in patients with low CV risk.
    Muñoz D; Granger CB
    Ann Intern Med; 2012 Apr; 156(8):JC4-07. PubMed ID: 22508747
    [No Abstract]   [Full Text] [Related]  

  • 11. ACP Journal Club. Glargine did not reduce CV events more than standard care in patients with dysglycemia.
    Lader E
    Ann Intern Med; 2012 Sep; 157(6):JC3-10, JC3-11. PubMed ID: 22986402
    [No Abstract]   [Full Text] [Related]  

  • 12. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose.
    DeFronzo RA; Abdul-Ghani M
    Am J Cardiol; 2011 Aug; 108(3 Suppl):3B-24B. PubMed ID: 21802577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACP Journal Club: Review: Low BP targets do not reduce mortality or CV events in hypertension.
    McAlister FA
    Ann Intern Med; 2009 Nov; 151(10):JC5-6-7. PubMed ID: 19920264
    [No Abstract]   [Full Text] [Related]  

  • 14. ACP Journal Club: metformin reduced CV events compared with glipizide in patients with type 2 diabetes and CAD.
    Tanner M
    Ann Intern Med; 2013 Apr; 158(8):JC4. PubMed ID: 23588769
    [No Abstract]   [Full Text] [Related]  

  • 15. ACP Journal Club. Rosiglitazone was noninferior to metformin plus sulfonylurea for CV events but increased risk for HF and fractures in type 2 diabetes.
    Lipscombe LL
    Ann Intern Med; 2009 Oct; 151(8):JC4-8. PubMed ID: 19841445
    [No Abstract]   [Full Text] [Related]  

  • 16. ACP Journal Club. Review: Aspirin does not reduce CV events but may reduce nonfatal stroke in peripheral artery disease.
    Mukherjee D
    Ann Intern Med; 2009 Sep; 151(6):JC3-5, JC3-4. PubMed ID: 19755351
    [No Abstract]   [Full Text] [Related]  

  • 17. ACP Journal Club. Review: Counseling and educational methods that target multiple CV risk factors do not reduce mortality in adults without CHD.
    Patel MJ; Newby LK
    Ann Intern Med; 2011 Jun; 154(12):JC6-4. PubMed ID: 21690582
    [No Abstract]   [Full Text] [Related]  

  • 18. ACP Journal Club. Benazepril plus amlodipine reduced CV events more than benazepril plus hydrochlorothiazide in hypertension with or without diabetes.
    Merugu S
    Ann Intern Med; 2010 Oct; 153(8):JC4-2. PubMed ID: 20956698
    [No Abstract]   [Full Text] [Related]  

  • 19. ACP Journal Club. Aspirin and/or antioxidants did not prevent CV events in diabetes and peripheral arterial disease.
    Farkouh ME
    Ann Intern Med; 2009 Jan; 150(2):JC1-8. PubMed ID: 19172713
    [No Abstract]   [Full Text] [Related]  

  • 20. Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study.
    Wong YW; Thomas L; Sun JL; McMurray JJ; Krum H; Hernandez AF; Rutten GE; Leiter LA; Standl E; Haffner SM; Mazzone T; Martinez FA; Tognoni G; Giles T; Califf RM
    Circ Heart Fail; 2013 Mar; 6(2):203-10. PubMed ID: 23388113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.